Rockwell Medical Technologies, Inc. Secures $1,000,000 in Equipment Lease Financing from GE Healthcare Financial Services

Business Wire, August 17, 2001

Business & Health/Medical Editors

WIXOM, Mich.--(BUSINESS WIRE)--Aug. 17, 2001

Rockwell Medical Technologies, Inc. (Nasdaq:RMTI), a leading, innovative hemodialysis concentrate manufacturer in the healthcare industry, announced today that it has signed a $1 million equipment lease financing agreement with GE Healthcare Financial Services.

The Company will fund capital spending for equipment in its new production facilities in Texas and Michigan with the proceeds from the lease financing agreement.

Under the terms of the agreement, dated August 15, 2001, the Company can acquire up to $1,000,000 in manufacturing equipment with payment terms over 60 months. The Company will expand production capacity of its Dri-Sate Dry Acid Concentrate product line in support of unit volume growth, which has increased by 44% in the first half of 2001 as compared to the first half of 2000.

Mr. Thomas E. Klema, Vice President and Chief Financial Officer stated, "This lease transaction is integral to our overall financing plan in support of the Company's growth strategy. This will provide us with the capability to fund our upgraded manufacturing operations and expansion. We see dual benefits of both improved productivity and capacity expansion that will facilitate Rockwell's growth and margin improvement."

"We are very pleased to have GE Healthcare support our growth strategy. With our overall sales up 33% in the first half of 2001 coupled with the strong market acceptance of our Dri-Sate Dry Acid Concentrate, we clearly see a need to expand our capacity to meet the growing demand for our products, both in the South with our new Texas facility and here in Michigan," stated Mr. Robert L. Chioini, Chairman & CEO.

Rockwell Medical Technologies, Inc., is an innovative leader in manufacturing, marketing and delivering high-quality dialysis solutions, powders and ancillary products to hemodialysis providers. Hemodialysis is a process that duplicates kidney function for patients whose kidneys have failed to function properly and suffer from end-stage renal disease (ESRD). There are an estimated 350,000 dialysis patients in the United States and the incidence of ESRD has increased 6-8% on average each year over the last decade. Rockwell offers Dri-Sate Dry Acid, Liquid Acid, SteriLyte(TM) Liquid Bicarbonate, Powder Bicarbonate and a wide range of ancillary dialysis items. Rockwell's products are used to cleanse the ESRD patient's blood and replace nutrients in the bloodstream. Visit Rockwell's website at www.rockwellmed.com for more information.

This press release contains forward-looking statements with respect to Rockwell's business and operations. Management of Rockwell believes the expectations reflected in the forward-looking statements made in this press release are based on reasonable assumptions. Certain factors could occur that might cause actual results to vary. These include, but are not limited to, general economic conditions, economic conditions in the hemodialysis industry, competitive factors and other factors discussed in Rockwell's reports filed with the Securities and Exchange Commission. The forward-looking statements should be considered in light of these risks and uncertainties.